BioMarin Pharmaceutical develops and sells therapies for rare genetic diseases (BMRN) Stock Forecast: What Could Drive It in 2026
Last updated July 2026
Short answer
What is actually driving BioMarin Pharmaceutical develops and sells therapies for rare genetic diseases (BMRN) right now is Voxzogo growth engine: Voxzogo, for children with achondroplasia, generated roughly $920 million in 2025 and remains the primary growth driver, with most sales coming from outside the United States. Revenue (2025) is ~$3.2B. If that keeps playing out, the setup is favourable; the risk to it is revenue is concentrated in a handful of products, so a setback for Voxzogo or a key enzyme therapy would weigh heavily on results. No one can predict where BMRN trades, and Walnut does not publish targets, so treat this as a scenario, not a price target or prediction.
What could drive BioMarin Pharmaceutical develops and sells therapies for rare genetic diseases (BMRN) higher?
1. Voxzogo growth engine
Voxzogo, for children with achondroplasia, generated roughly $920 million in 2025 and remains the primary growth driver, with most sales coming from outside the United States. BioMarin is pursuing label expansions and additional indications that could widen the addressable population. Continued patient additions are central to the company's raised 2026 outlook.
2. Amicus acquisition and portfolio breadth
The roughly $4.8 billion Amicus deal, completed in April 2026, added Galafold for Fabry disease and Pombiliti plus Opfolda for Pompe disease. Management expects the deal to be slightly dilutive to 2026 non-GAAP earnings but accretive starting in 2027. Successful integration diversifies revenue beyond the legacy enzyme therapies and Voxzogo.
3. Enzyme therapy base and margins
Established enzyme replacement products such as Vimizim, Naglazyme and Palynziq provide a stable, high-margin cash-generating base with long orphan-drug exclusivity. This recurring revenue funds research and the pipeline. Double-digit growth across enzyme therapies contributed to record 2025 revenue.
4. Pipeline optionality
BioMarin is advancing internal programs including BMN 333, BMN 351 and BMN 401, alongside further Voxzogo indications. These earlier-stage assets offer longer-term upside if trials read out well. The company has also shown willingness to prune assets, as with the Roctavian withdrawal, to focus resources.
What could weigh on BMRN?
Revenue is concentrated in a handful of products, so a setback for Voxzogo or a key enzyme therapy would weigh heavily on results. Rare-disease pricing draws scrutiny from payers and governments, and much of Voxzogo's revenue comes from international markets subject to reimbursement pressure. Competition is emerging, including Ascendis Pharma's TransCon CNP in achondroplasia and multiple Fabry and Pompe therapies from larger rivals. The Amicus acquisition adds integration and execution risk, and the Roctavian withdrawal shows that expensive programs can fail commercially. The shares trade at a premium multiple, leaving little margin for disappointment.
Where BMRN trades today
A forecast starts from where the stock actually is. These are BMRN's current figures, not a projection: the drivers and risks above are what would move them.
Snapshot for BMRN as of July 2026, sourced from Yahoo Finance and may be delayed. Valuation figures move with price and earnings; verify the current numbers with your broker before deciding.
How to think about a BMRN forecast
Rather than chasing a price target, it tends to help to weigh the drivers above against the risks, decide how long you are willing to hold, and size the position so a wrong call is survivable. A “forecast” is really a probability-weighted view of those drivers playing out, not a number.
For the full picture, see the BMRN guide and whether BMRN is a buy. In Walnut you can pressure-test the thesis against your real portfolio.
The bottom line on the BMRN outlook
The bottom line: what is driving BioMarin Pharmaceutical develops and sells therapies for rare genetic diseases (BMRN) is Voxzogo growth engine, with revenue (2025) at ~$3.2B. If that keeps playing out the setup is favourable; the risk is revenue is concentrated in a handful of products, so a setback for Voxzogo or a key enzyme therapy would weigh heavily on results. No one can predict the price, so treat any BMRN forecast as a scenario, not a target or prediction, and decide from your own thesis and time horizon. Walnut is not an investment adviser.
Build a basket around BMRN with Walnut
Use BioMarin Pharmaceutical develops and sells therapies for rare genetic diseases as one constituent in a thematic basket Walnut's AI helps you assemble. Describe a thesis you believe in, the AI proposes the holdings and weights, and you approve before any broker order.
FAQ
What is the forecast for BioMarin Pharmaceutical develops and sells therapies for rare genetic diseases (BMRN)?
+
No one can reliably predict where BMRN will trade, and Walnut does not publish price targets. What is more useful is the setup: the drivers that could push BioMarin Pharmaceutical develops and sells therapies for rare genetic diseases higher and the risks that could weigh on it. This page lays out both so you can form your own view. Not a recommendation.
What could drive BMRN higher?
+
The main growth drivers are Voxzogo growth engine; Amicus acquisition and portfolio breadth; Enzyme therapy base and margins. Whether they play out is the real question, not a guaranteed path.
What are the risks to BMRN?
+
Revenue is concentrated in a handful of products, so a setback for Voxzogo or a key enzyme therapy would weigh heavily on results. Rare-disease pricing draws scrutiny from payers and governments, and much of Voxzogo's revenue comes from international markets subject to reimbursement pressure. Competition is emerging, including Ascendis Pharma's TransCon CNP in achondroplasia and multiple Fabry and Pompe therapies from larger rivals. The Amicus acquisition adds integration and execution risk, and the Roctavian withdrawal shows that expensive programs can fail commercially. The shares trade at a premium multiple, leaving little margin for disappointment.
Will BMRN stock go up in 2026?
+
Nobody knows, and anyone who says they do is guessing. BioMarin Pharmaceutical develops and sells therapies for rare genetic diseases's direction depends on whether the drivers above outweigh the risks, plus the broader market. Focus on the thesis and your time horizon rather than a single-year call.
Is BMRN a buy?
+
That depends on your thesis, time horizon, and what you already own, not on a forecast. See the BMRN "is it a buy?" page for a framework. Walnut is not an investment adviser.
What is BioMarin's biggest growth driver?
+
Voxzogo, its treatment for children with achondroplasia, is the fastest-growing product, generating roughly $920 million in 2025. Continued patient additions and potential label expansions make it central to the company's raised 2026 outlook, alongside the newly acquired Amicus products.
Walnut is informational, not investment advice. This page describes drivers and risks; it is not a price forecast, target, or recommendation. Markets are uncertain and past performance does not predict future results.